Journal of Diabetes Science and Technology · 2014 · 52 citations · 6 references
PharmacyPharmaceuticsPharmacokineticsBioavailabilityDrug DeliveryPharmaceutical FormulationDrug Delivery SystemsGlucagon TherapyChemical Stability CriteriaChemical Stability TestingGlucagon PharmacodynamicsGlucagon PharmacokineticsInfusion Pump SystemsRabbit ModelsStability Of Glucagon FormulationsSubcutaneous Glucagon
Despite a vigorous research effort, to date, the development of systems that achieve glucagon stability in aqueous formulations (without reconstitution) has failed to produce any clinical candidates. We have developed a novel, nonaqueous glucagon formulation based on a biocompatible pharmaceutical solvent, dimethyl sulfoxide, which demonstrates excellent physical and chemical stability at relatively high concentrations and at high temperatures. This article reports the development of a novel, biocompatible, nonaqueous native human glucagon formulation for potential use in subcutaneous infusion pump systems. Data are presented that demonstrate physical and chemical stability under presumed storage conditions (>2 years at room temperature) as well as "in use" stability and compatibility in an Insulet's OmniPod(®) infusion pump. Also presented are results of a skin irritation study in a rabbit model and pharmacokinetics/pharmacodynamics data following pump administration of glucagon in a diabetic swine model. This nonaqueous glucagon formulation is suitable for further clinical development in pump systems.
6